Quick Answer
Monopar Therapeutics reported Net Income Loss of -$13.72 million for the year ending 2025.
- Monopar Therapeutics showed an increase of +12.0% in Net Income Loss from 2024 to 2025.
- This data is from Monopar Therapeutics's annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Monopar Therapeutics's Net Income Loss has declined by 1,057.0%.
- Historical annual values: Fiscal year 2025: -$13.72 million | Fiscal year 2024: -$15.59 million | Fiscal year 2023: -$8.40 million | Fiscal year 2022: -$10.52 million | Fiscal year 2021: -$9.10 million | Fiscal year 2020: -$6.30 million | Fiscal year 2019: -$4.22 million | Fiscal year 2018: -$3.23 million | Fiscal year 2017: -$16.55 million | Fiscal year 2016: -$1.19 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: